NCT03203525 2026-02-25
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
M.D. Anderson Cancer Center
Sumitomo Pharma America, Inc.
M.D. Anderson Cancer Center
Tesaro, Inc.
Sanofi
University of Southern California